I'm pleased to present a new-look Ethical Equites.

But more than that, I'm grateful that Max Rozen built this site for us on his weekends. If you have a website that needs help, you could reach out to him!

In refreshing the site it was funny to see some of the draft posts I wrote, but never published. I was essentially unable to write for Ethical Equities from October 2014 until August 2018. Fair enough, but it did mean this piece was stuck in drafts. Given the Pro Medicus (ASX:PME) price was around $1.30 at the time I naively drafted it, it would have been nice to get that out to EE readers, back then. Oh well.

The point is that it feels good to have this website working again. And it feels even better to have the support of other thoughtful investors to build it up.

I'm also pleased to announce that we now have Forums so if you have any questions, thoughts to share (or simply want to say hello), please jump on and start a thread (you have to sign up, but this is not an email list, it's just for access to the forums, to stop spam). Eventually I aim to phase out comments at the bottom of articles.

Also good news is the fact that the website is now built to manage a paywall. That's good for everyone because if we are to supply a steady (and increasing) stream of high quality content, we'll need money to pay the small band of merry writers who actually put the effort in.

I'm talking about earnings coverage that is more than a copy + paste of the press release or results presentation. Real analysis, thoughtfully written and edited. In an age where many tipsters and traders think 'less is more', Ethical Equities says 'more is more'; as long as the prose has extensive thought, research, and consideration behind it.

Obviously, that's a niche -- many people just want to be told exactly what to do. But it's a nice niche to live in -- and that's where my friends and I will be.

For exclusive content, join the Ethical Equities Newsletter.

Disclosure: Claude Walker own shares in Pro Medicus. This article contains general investment advice only (under AFSL 501223). Authorised by Claude Walker.